This Article Full Text Full Text (PDF) All Versions of this Article: 37/8/2165    most recent 01.STR.0000231842.32153.74v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foerch, C. Search for Related Content PubMed PubMed Citation Articles by Foerch, C. Related Collections Anticoagulants Antiplatelets Platelet function inhibitors Acute Cerebral Hemorrhage

(Stroke. 2006;37:2165.)
© 2006 American Heart Association, Inc.

Research Reports

Pretreatment With Antiplatelet Agents Is Not Independently Associated With Unfavorable Outcome in Intracerebral Hemorrhage

Christian Foerch, MD; Matthias Sitzer, MD; Helmuth Steinmetz, MD; Tobias Neumann-Haefelin, MD for the Arbeitsgruppe Schlaganfall Hessen

From the Department of Neurology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.

Correspondence to Christian Foerch, MD, Department of Neurology, Johann Wolfgang Goethe University, Schleusenweg 2-16, 60528 Frankfurt am Main, Germany. E-mail foerch{at}em.uni-frankfurt.de

Background and Purpose— This study investigated the effect of preexisting antiplatelet therapy on mortality and functional outcome in patients with intracerebral hemorrhage (ICH).

Methods— Our analysis was based on a large, country-wide stroke registry in Germany. All parameters relevant to this analysis, including age, prehospital status (according to the modified Rankin Scale, mRS), International Classification of Diseases–based diagnosis, and pretreatment with antiplatelet agents or oral anticoagulants, were recorded prospectively. Main outcome measures were in-hospital mortality rate and functional status at hospital discharge (mRS).

Results— Over a 2-year period, 1691 patients with ICH (ICD-10: I61) were documented (48% female; mean age, 72±12 years). At symptom onset, 26% were taking antiplatelet agents, and 12% were taking oral anticoagulants. By univariate logistic regression, pretreatment with antiplatelet drugs or anticoagulants was found to be a significant predictor of in-hospital mortality (odds ratio [OR], 1.42; P=0.008; OR, 1.53; P<0.001) and of an unfavorable functional outcome (defined as mRS >2 or death; OR, 1.33, P=0.039; OR, 1.51; P<0.001). However, after adjustment for age and prehospital status, antiplatelet pretreatment was no longer an independent risk factor of in-hospital death (OR, 1.12; P=0.490) or unfavorable functional outcome (OR, 0.97; P=0.830), whereas the influence of pretreatment with oral anticoagulants remained significant (OR, 1.45; P<0.001; OR, 1.42; P=0.009).

Conclusions— In contrast to oral anticoagulants, pretreatment with antiplatelet agents is not an independent risk factor of mortality and unfavorable outcome in patients with ICH.

Key Words: antiplatelet agents • cerebral hemorrhage • outcome

This article has been cited by other articles:

				G. J. Spalding, M. Hartrumpf, T. Sierig, N. Oesberg, C. G. Kirschke, and J. M. Albes Cost reduction of perioperative coagulation management in cardiac surgery: value of 'bedside' thrombelastography (ROTEM) Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1052 - 1057. [Abstract] [Full Text] [PDF]

				J. Roquer Previous Antiplatelet Treatment and Mortality in Patients With Intracerebral Hemorrhage Stroke, March 1, 2007; 38(3): 863 - 863. [Full Text] [PDF]

				C. Foerch and T. Neumann-Haefelin Response to Letter by Roquer Stroke, March 1, 2007; 38(3): 864 - 864. [Full Text] [PDF]